NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
Clinical Trials
13 trialsNCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT01679743 2019-11-15
GRN1005 for Brain Metastases From Breast or Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03766607 2019-09-19
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Korean South West Oncology Group
Phase 2 Withdrawn
NCT03058939 2019-04-22
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Withdrawn
NCT01205217 2017-06-07
ELATE
GlaxoSmithKline
Phase 2 Withdrawn
NCT00964704 2016-11-02
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Withdrawn
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT01557764 2013-07-04
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT00434031 2012-07-30
CETRA
National Cancer Institute, Naples
Phase 2 Withdrawn
NCT00054470 2012-06-29
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT00057993 2012-06-11
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Northwestern University
Phase 2 Withdrawn